Core Viewpoint - 康希诺的H股上涨6.7%，主要因其吸入用结核病加强疫苗在印尼启动I期临床试验 [1] Company Summary - 康希诺的H股在市场上表现良好，涨幅达到6.7% [1] - 吸入用结核病加强疫苗的I期临床试验在印尼正式启动，这标志着公司在疫苗研发方面的重要进展 [1] Industry Summary - 吸入用疫苗的临床试验可能会推动结核病疫苗市场的发展，提升行业对新型疫苗的关注 [1]

Major Events - Shanghai Industrial Holdings (00363) plans to sell 49% stake in Shanghai Shanshi Medical Beauty Hospital for 73.598 million yuan [1] - Hengrui Medicine (01276) received approval for clinical trial of Rivoceranib tablets [1] - CanSino Biologics (06185) initiated Phase I clinical trial of inhaled tuberculosis vaccine in Indonesia, completing the enrollment of the first subject [1] - Zhonghui Biotech-B (02627) started Phase I clinical trials for quadrivalent and trivalent influenza virus subunit vaccines [1] - Zhiyun Health (09955) signed a service cooperation agreement with JD Health (06618) to expand online sales and service channels for Livermore tablets and other P2M pipeline products [1] - China Resources Land (01109) plans to place shares of China Resources Mixc Lifestyle (01209) to diversify shareholder structure [1] - Shoucheng Holdings (00697) announced investment in Star Motion Era by Beijing Robotics Fund [1] Financial Performance - Tencent Holdings (00700) reported third-quarter revenue and profit growth, with non-IFRS profit attributable to shareholders reaching 70.551 billion yuan [1] - JD Group-SW (09618) reported third-quarter total revenue of 299.059 billion yuan, a year-on-year increase of 14.85% [1] - JD Logistics (02618) reported third-quarter revenue of 55.084 billion yuan, a year-on-year growth of 24.1% [1] - JD Health (06618) reported third-quarter operating profit of 1.243 billion yuan, a year-on-year increase of 125.3% [1] - SMIC (00981) reported third-quarter profit attributable to shareholders of approximately 192 million USD, a quarter-on-quarter increase of 44.7% and a year-on-year increase of 28.9% [1] - Bilibili-W (09626) reported a net profit of 469 million yuan in the third quarter, turning profitable year-on-year, with all core user metrics reaching historical highs [1] - China Pacific Insurance (02601) reported original insurance premium income of 241.322 billion yuan for the first ten months, a year-on-year increase of 9.9% [1]

转自：证券时报 人民财讯11月13日电，康希诺(688185)11月13日公告，公司开发的吸入用肺结核疫苗（5型腺病毒载 体）（简称"吸入用结核病加强疫苗"）近日于印度尼西亚启动I期临床试验，并完成Ⅰ期临床首例受试 者入组。 ...

I期临床试验于印度尼西亚开展，目的是在18至49岁的成年人中探究接种一剂吸入用结核病加强疫苗的 安全性和免疫原性。 目前，卡介苗是全球唯一可用于预防结核病的疫苗，在全球范围内被广泛接种，其对预防婴幼儿结核病 发挥重要作用，但卡介苗保护力会随时间减弱，无法通过加强免疫接种增强疫苗的保护效果。针对此不 足，公司研发了第一代全球创新结核病加强疫苗用于卡介苗接种人群，结核病加强疫苗于加拿大完成了 Ia及Ib期临床试验，临床试验数据证明了结核病加强疫苗作为候选疫苗的安全性和作为卡介苗加强疫苗 的有效性，以及黏膜免疫的优越性。 基于吸入用新冠疫苗开发的技术累积，公司建立了完整的吸入药学、质量控制体系，升级第一代产品， 同时增加了抗原组分，开发了吸入用结核病加强疫苗，通过雾化吸入的方式递送，有望可以激发肺部免 疫应答，从而清除结核菌，控制潜伏感染，并可实现预防感染的效果。 智通财经APP讯，康希诺生物(06185)发布公告，公司开发的吸入用肺结核疫苗(5型腺病毒载体)近日于 印度尼西亚正式启动I期临床试验，并完成I期临床试验首例受试者入组。 ...

Core Viewpoint - The company has initiated Phase I clinical trials for its inhaled tuberculosis vaccine in Indonesia, marking a significant step in its development of a novel vaccine to enhance protection against tuberculosis [1] Group 1: Vaccine Development - The inhaled tuberculosis vaccine, developed using a 5-type adenoviral vector, has officially started its Phase I clinical trials in Indonesia, with the first subject enrolled [1] - The existing BCG vaccine is the only globally available vaccine for tuberculosis prevention, but its efficacy diminishes over time and cannot be enhanced through booster shots [1] - The company has developed a first-generation innovative tuberculosis booster vaccine aimed at individuals who have received the BCG vaccine, which has shown safety and efficacy in previous clinical trials conducted in Canada [1] Group 2: Technological Advancements - The company has leveraged its technology from the development of inhaled COVID-19 vaccines to establish a comprehensive inhalation pharmaceutical and quality control system [1] - The upgraded inhaled tuberculosis booster vaccine includes additional antigen components and is designed to be delivered via nebulization, potentially stimulating pulmonary immune responses to eliminate tuberculosis bacteria and control latent infections [1]

Core Viewpoint - The company has initiated Phase I clinical trials for its inhaled tuberculosis vaccine in Indonesia, marking a significant step in its vaccine development efforts [1] Group 1: Vaccine Development - The inhaled tuberculosis vaccine, developed using a 5-type adenovirus vector, aims to enhance immunity in individuals previously vaccinated with the BCG vaccine [1] - The BCG vaccine is currently the only vaccine available for tuberculosis prevention, but its efficacy diminishes over time, necessitating the development of a booster vaccine [1] - The company has successfully completed Phase Ia and Ib clinical trials in Canada, demonstrating the safety and efficacy of the tuberculosis booster vaccine [1] Group 2: Technological Advancements - The company has leveraged its experience from developing inhaled COVID-19 vaccines to establish a comprehensive inhalation pharmaceutical and quality control system [1] - The upgraded inhaled tuberculosis booster vaccine includes additional antigen components and is designed to be delivered via nebulization, potentially stimulating pulmonary immune responses [1] - This innovative delivery method aims to clear tuberculosis bacteria, control latent infections, and provide preventive effects against the disease [1]

CanSino Biologics Inc. 康希諾生物股份公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6185） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部 或任何部分內容所產生或因依賴該等內容而引致的任何損失承擔任何責任。 基 於 吸 入 用 新 冠 疫 苗 開 發 的 技 術 累 積，本 公 司 建 立 了 完 整 的 吸 入 藥 學、質 量 控 制體系，升級第一代產品，同時增加了抗原組分，開發了吸入用結核病加強疫苗， 通過霧化吸入的方式遞送，有望可以激發肺部免疫應答，從而清除結核菌，控制 潛伏感染，並可實現預防感染的效果。 – 1 – I期臨床試驗於印度尼西亞開展，目的是在18至49歲的成年人中探究接種一劑吸 入用結核病加強疫苗的安全性和免疫原性。 本公司股東及潛在投資者在買賣本公司股份時務請審慎行事。 承董事會命 康希諾生物股份公司 自願公告 吸入用結核病加強疫苗於印度尼西亞 啟 動I期臨床試驗並完成首例受試者入組 本 公 告 由 康 希 諾 生 物 股 份 公 司（「本公司」）自 願 ...

康希诺(688185.SH)发布公告，公司开发的吸入用肺结核疫苗(5型腺病毒载体)(简称"吸入用结核病加强 疫苗")近日于印度尼西亚启动I期临床试验，并完成I期临床首例受试者入组。 该I期临床试验于印度尼西亚开展，目的是在18-49岁的成年人中探究接种一剂吸入用肺结核疫苗(5型腺 病毒载体)的安全性和免疫原性。 ...

智通财经APP讯，康希诺(688185.SH)发布公告，公司开发的吸入用肺结核疫苗(5型腺病毒载体)(简称"吸 入用结核病加强疫苗")近日于印度尼西亚启动I期临床试验，并完成I期临床首例受试者入组。 该I期临床试验于印度尼西亚开展，目的是在18-49岁的成年人中探究接种一剂吸入用肺结核疫苗(5型腺 病毒载体)的安全性和免疫原性。 ...

Group 1: Company Performance - NetEase-S (09999) saw a significant increase of 10.89% in stock price after reporting Q1 2025 net revenue of RMB 28.8285 billion, a year-on-year increase of 7.4%, and gross profit of RMB 18.5 billion, up 8.6% [1] - H&H International Holdings (01112) rose over 8% as the market speculated on the ergotamine concept, with its Swisse brand showing strong performance in high-growth segments [2] - China Gold International (02099) experienced a stock price increase of over 5% after reporting a 351% rise in Q1 revenue to USD 273 million [2] Group 2: Clinical and Pharmaceutical Developments - Shandong Xinhua Pharmaceutical (00719) surged over 14% as COVID-19 infections showed an upward trend, with the company preparing for Phase II clinical trials of OAB-14 [1] - Innovent Biologics (01801) rose nearly 3% after announcing the completion of the first patient dosing in the Phase III clinical study of Ma Shidu peptide for obesity [1] - Kangxi Biologics (06185) increased over 3% after receiving approval from the Indonesian drug regulatory authority for its inhaled tuberculosis vaccine clinical trial [1] Group 3: Market Trends and Reactions - The Nasdaq Golden Dragon China Index fell over 2%, with notable declines in popular Chinese stocks such as Tiger Brokers (TIGR.US) down over 8% and Beike (BEKE.US) down over 5% [3] - UnitedHealth Group (UNH.US) experienced a significant drop of over 15% following reports of a U.S. Department of Justice investigation into potential insurance fraud [3] - Bitcoin-related stocks declined, with CleanSpark (CLSK.US) down nearly 6% and Coinbase (COIN.US) down over 7%, as Bitcoin itself fell over 1.5% [3]